These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 31403177)

  • 1. Progesterone receptor status modifies the association between body mass index and prognosis in women diagnosed with estrogen receptor positive breast cancer.
    Oudanonh T; Nabi H; Ennour-Idrissi K; Lemieux J; Diorio C
    Int J Cancer; 2020 May; 146(10):2736-2745. PubMed ID: 31403177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer.
    Li Y; Yang D; Yin X; Zhang X; Huang J; Wu Y; Wang M; Yi Z; Li H; Li H; Ren G
    JAMA Netw Open; 2020 Jan; 3(1):e1918160. PubMed ID: 31899528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Body weight at age 20 years, subsequent weight change and breast cancer risk defined by estrogen and progesterone receptor status--the Japan public health center-based prospective study.
    Suzuki R; Iwasaki M; Inoue M; Sasazuki S; Sawada N; Yamaji T; Shimazu T; Tsugane S;
    Int J Cancer; 2011 Sep; 129(5):1214-24. PubMed ID: 21064092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High fasting blood glucose and obesity significantly and independently increase risk of breast cancer death in hormone receptor-positive disease.
    Minicozzi P; Berrino F; Sebastiani F; Falcini F; Vattiato R; Cioccoloni F; Calagreti G; Fusco M; Vitale MF; Tumino R; Sigona A; Budroni M; Cesaraccio R; Candela G; Scuderi T; Zarcone M; Campisi I; Sant M
    Eur J Cancer; 2013 Dec; 49(18):3881-8. PubMed ID: 24011933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study.
    Ritte R; Lukanova A; Berrino F; Dossus L; Tjønneland A; Olsen A; Overvad TF; Overvad K; Clavel-Chapelon F; Fournier A; Fagherazzi G; Rohrmann S; Teucher B; Boeing H; Aleksandrova K; Trichopoulou A; Lagiou P; Trichopoulos D; Palli D; Sieri S; Panico S; Tumino R; Vineis P; Quirós JR; Buckland G; Sánchez MJ; Amiano P; Chirlaque MD; Ardanaz E; Sund M; Lenner P; Bueno-de-Mesquita B; van Gils CH; Peeters PH; Krum-Hansen S; Gram IT; Lund E; Khaw KT; Wareham N; Allen NE; Key TJ; Romieu I; Rinaldi S; Siddiq A; Cox D; Riboli E; Kaaks R
    Breast Cancer Res; 2012 May; 14(3):R76. PubMed ID: 22583394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival.
    Jeon YW; Kang SH; Park MH; Lim W; Cho SH; Suh YJ
    BMC Cancer; 2015 Nov; 15():865. PubMed ID: 26546331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct Effects of Body Mass Index and Waist/Hip Ratio on Risk of Breast Cancer by Joint Estrogen and Progestogen Receptor Status: Results from a Case-Control Study in Northern and Eastern China and Implications for Chemoprevention.
    Wang F; Liu L; Cui S; Tian F; Fan Z; Geng C; Cao X; Yang Z; Wang X; Liang H; Wang S; Jiang H; Duan X; Wang H; Li G; Wang Q; Zhang J; Jin F; Tang J; Li L; Zhu S; Zuo W; Ma Z; Zhou F; Yu L; Xiang Y; Li L; Shen S; Yu Z
    Oncologist; 2017 Dec; 22(12):1431-1443. PubMed ID: 28912152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hip circumference is associated with the risk of premenopausal ER-/PR- breast cancer.
    Fagherazzi G; Chabbert-Buffet N; Fabre A; Guillas G; Boutron-Ruault MC; Mesrine S; Clavel-Chapelon F
    Int J Obes (Lond); 2012 Mar; 36(3):431-9. PubMed ID: 21427693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Body weight and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status among Swedish women: A prospective cohort study.
    Suzuki R; Rylander-Rudqvist T; Ye W; Saji S; Wolk A
    Int J Cancer; 2006 Oct; 119(7):1683-9. PubMed ID: 16646051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adult body size and physical activity in relation to risk of breast cancer according to tumor androgen receptor status.
    Zhang X; Eliassen AH; Tamimi RM; Hazra A; Beck AH; Brown M; Collins LC; Rosner B; Hankinson SE
    Cancer Epidemiol Biomarkers Prev; 2015 Jun; 24(6):962-8. PubMed ID: 25855627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
    Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
    Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Body mass index at age 18 years and recent body mass index in relation to risk of breast cancer overall and ER/PR/HER2-defined subtypes in white women and African-American women: a pooled analysis.
    Ma H; Ursin G; Xu X; Lee E; Togawa K; Malone KE; Marchbanks PA; McDonald JA; Simon MS; Folger SG; Lu Y; Sullivan-Halley J; Deapen DM; Press MF; Bernstein L
    Breast Cancer Res; 2018 Jan; 20(1):5. PubMed ID: 29357906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of body mass index on survival outcome among women with early stage triple-negative breast cancer.
    Dawood S; Lei X; Litton JK; Buchholz TA; Hortobagyi GN; Gonzalez-Angulo AM
    Clin Breast Cancer; 2012 Oct; 12(5):364-72. PubMed ID: 23040004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
    Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
    Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Racial/Ethnic Disparities in Survival after Breast Cancer Diagnosis by Estrogen and Progesterone Receptor Status: A Pooled Analysis.
    John EM; McGuire V; Kurian AW; Koo J; Shariff-Marco S; Gomez SL; Cheng I; Keegan THM; Kwan ML; Bernstein L; Vigen C; Wu AH
    Cancer Epidemiol Biomarkers Prev; 2021 Feb; 30(2):351-363. PubMed ID: 33355191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis.
    Niraula S; Ocana A; Ennis M; Goodwin PJ
    Breast Cancer Res Treat; 2012 Jul; 134(2):769-81. PubMed ID: 22562122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postmenopausal obesity as a breast cancer risk factor according to estrogen and progesterone receptor status (Japan).
    Yoo K; Tajima K; Park S; Kang D; Kim S; Hirose K; Takeuchi T; Miura S
    Cancer Lett; 2001 Jun; 167(1):57-63. PubMed ID: 11323099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The associations of obesity, lymph node status and prognosis in breast cancer patients: dependence on estrogen and progesterone receptor status.
    Maehle BO; Tretli S; Thorsen T
    APMIS; 2004 Jun; 112(6):349-57. PubMed ID: 15511272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for hormone receptor-defined breast cancer in postmenopausal women.
    Rosenberg LU; Einarsdóttir K; Friman EI; Wedrén S; Dickman PW; Hall P; Magnusson C
    Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2482-8. PubMed ID: 17164374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.